Passage Bio Inc. presented updates on its gene therapy program PBFT02, which targets frontotemporal dementia with progranulin gene mutations (FTD-GRN). The therapy is designed as a one-time, proprietary AAV1 gene replacement administered via nonsurgical injection to the cerebrospinal fluid, aiming to restore progranulin levels and address the underlying cause of FTD-GRN. Interim clinical data indicate durable elevation of progranulin in treated patients. The company highlighted the significant market opportunity for PBFT02 across several neurodegenerative diseases, including ALS and Alzheimer's disease associated with GRN mutations. Passage Bio also reported that its current cash position is expected to support operations into the first quarter of 2027. You can access the full presentation through the link below.